#$LGVN weekly close $1.67 (+4.4% w/w), below SMA50 $3.90 / below SMA200 $6.64, RSI 31.2. Support $1.31, resistance $2.69. Broad market sell-off Friday.
Oct 26: ELPIS II update, primary missed, MACE secondary significant.
New hub updated: www.merlintrader.com/longeveron-l...
Oct 26: ELPIS II update, primary missed, MACE secondary significant.
New hub updated: www.merlintrader.com/longeveron-l...
November 1, 2026 at 2:21 PM
#$LGVN weekly close $1.67 (+4.4% w/w), below SMA50 $3.90 / below SMA200 $6.64, RSI 31.2. Support $1.31, resistance $2.69. Broad market sell-off Friday.
Oct 26: ELPIS II update, primary missed, MACE secondary significant.
New hub updated: www.merlintrader.com/longeveron-l...
Oct 26: ELPIS II update, primary missed, MACE secondary significant.
New hub updated: www.merlintrader.com/longeveron-l...
$LGVN 🤝
Longeveron Inc. retained Lucid Capital Markets, LLC as financial advisor to explore strategic opportunities, including a potential business combination.
Timely market event
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
Longeveron Inc. retained Lucid Capital Markets, LLC as financial advisor to explore strategic opportunities, including a potential business combination.
Timely market event
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
October 28, 2026 at 1:16 PM
$LGVN 🤝
Longeveron Inc. retained Lucid Capital Markets, LLC as financial advisor to explore strategic opportunities, including a potential business combination.
Timely market event
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
Longeveron Inc. retained Lucid Capital Markets, LLC as financial advisor to explore strategic opportunities, including a potential business combination.
Timely market event
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
#LGVN Longeveron Announces Engagement of Lucid Capital Markets
https://www.stocktitan.net/news/LGVN/longeveron-announces-engagement-of-lucid-capital-qddvytptcorp.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/LGVN/longeveron-announces-engagement-of-lucid-capital-qddvytptcorp.html?utm_source=stocktitan-bluesky&utm_medium=social
Longeveron Announces Engagement of Lucid Capital Markets
Longeveron (NASDAQ: LGVN) has retained Lucid Capital Markets as its financial advisor to explore potential strategic opportunities for the company. Those opportunities include a potential business combination; the engagement is exploratory.
www.stocktitan.net
October 28, 2026 at 1:15 PM
#LGVN Longeveron Announces Engagement of Lucid Capital Markets
https://www.stocktitan.net/news/LGVN/longeveron-announces-engagement-of-lucid-capital-qddvytptcorp.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/LGVN/longeveron-announces-engagement-of-lucid-capital-qddvytptcorp.html?utm_source=stocktitan-bluesky&utm_medium=social
$LGVN Oct 28, 2026: Longeveron retained Lucid Capital Markets as financial advisor to explore strategic opportunities, including a potential business combination. No transaction has been announced.
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
Longeveron ($LGVN): Frailty And XPRIZE After ELPIS II
Longeveron after the ELPIS II miss: frailty and XPRIZE data, Alzheimer’s analyses, cash guided into Q4 2026, dilution and the review of all options.
www.merlintrader.com
October 28, 2026 at 3:52 PM
$LGVN Oct 28, 2026: Longeveron retained Lucid Capital Markets as financial advisor to explore strategic opportunities, including a potential business combination. No transaction has been announced.
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
$LGVN Oct 28, 2026: Longeveron retained Lucid Capital Markets as financial advisor to explore strategic opportunities, including a potential business combination. No transaction has been announced.
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
Longeveron ($LGVN): Frailty And XPRIZE After ELPIS II
Longeveron after the ELPIS II miss: frailty and XPRIZE data, Alzheimer’s analyses, cash guided into Q4 2026, dilution and the review of all options.
www.merlintrader.com
October 28, 2026 at 3:52 PM
$LGVN Oct 28, 2026: Longeveron retained Lucid Capital Markets as financial advisor to explore strategic opportunities, including a potential business combination. No transaction has been announced.
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
$LGVN updated ELPIS II: the primary endpoint was not met, but MACE was 1 vs 8 (p=0.043) on a secondary endpoint. Presentation planned for AHA on November 8.
Not investment advice.
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
Not investment advice.
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
October 26, 2026 at 8:38 PM
$LGVN updated ELPIS II: the primary endpoint was not met, but MACE was 1 vs 8 (p=0.043) on a secondary endpoint. Presentation planned for AHA on November 8.
Not investment advice.
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
Not investment advice.
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
🚨 $LGVN
On October 26, 2026, Longeveron Inc. a clinical-stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, issued a press release announcing updated results from ELPIS II, its Phase 2b clinical trial evaluating the ...
On October 26, 2026, Longeveron Inc. a clinical-stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, issued a press release announcing updated results from ELPIS II, its Phase 2b clinical trial evaluating the ...
SEC Filing: LGVN
Click to view the official SEC document.
www.sec.gov
October 26, 2026 at 8:45 PM
🚨 $LGVN
On October 26, 2026, Longeveron Inc. a clinical-stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, issued a press release announcing updated results from ELPIS II, its Phase 2b clinical trial evaluating the ...
On October 26, 2026, Longeveron Inc. a clinical-stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, issued a press release announcing updated results from ELPIS II, its Phase 2b clinical trial evaluating the ...
#LGVN Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treat…
https://www.stocktitan.net/news/LGVN/longeveron-announces-updated-results-from-elpis-ii-phase-2b-clinical-373shzdmqql0.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/LGVN/longeveron-announces-updated-results-from-elpis-ii-phase-2b-clinical-373shzdmqql0.html?utm_source=stocktitan-bluesky&utm_medium=social
Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 26, 2026 at 1:15 PM
#LGVN Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treat…
https://www.stocktitan.net/news/LGVN/longeveron-announces-updated-results-from-elpis-ii-phase-2b-clinical-373shzdmqql0.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/LGVN/longeveron-announces-updated-results-from-elpis-ii-phase-2b-clinical-373shzdmqql0.html?utm_source=stocktitan-bluesky&utm_medium=social
October 14, 2026: Longeveron's chief medical officer, Dr. Nataliya Agafonova, stepped down; the 8-K names no successor. $LGVN
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
Longeveron ($LGVN): Frailty And XPRIZE After ELPIS II
Longeveron after the ELPIS II miss: frailty and XPRIZE data, Alzheimer’s analyses, cash guided into Q4 2026, dilution and the review of all options.
www.merlintrader.com
October 15, 2026 at 3:21 PM
October 14, 2026: Longeveron's chief medical officer, Dr. Nataliya Agafonova, stepped down; the 8-K names no successor. $LGVN
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
"Renforcer la lutte contre l'insécurité dans le centre-ville de Nantes" : quelles sont les mesures annoncées ?
➡️ https://l.actu.fr/LGvn
➡️ https://l.actu.fr/LGvn
October 15, 2026 at 8:30 AM
"Renforcer la lutte contre l'insécurité dans le centre-ville de Nantes" : quelles sont les mesures annoncées ?
➡️ https://l.actu.fr/LGvn
➡️ https://l.actu.fr/LGvn
🚨 $LGVN
(b) On October 7, 2026, Dr. Nataliya Agafonova informed management of Longeveron Inc. of her decision to step down as Chief Medical Officer, to become effective October 14, 2026. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly cause...
(b) On October 7, 2026, Dr. Nataliya Agafonova informed management of Longeveron Inc. of her decision to step down as Chief Medical Officer, to become effective October 14, 2026. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly cause...
SEC Filing: LGVN
Click to view the official SEC document.
www.sec.gov
October 14, 2026 at 8:02 PM
🚨 $LGVN
(b) On October 7, 2026, Dr. Nataliya Agafonova informed management of Longeveron Inc. of her decision to step down as Chief Medical Officer, to become effective October 14, 2026. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly cause...
(b) On October 7, 2026, Dr. Nataliya Agafonova informed management of Longeveron Inc. of her decision to step down as Chief Medical Officer, to become effective October 14, 2026. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly cause...
🚨 $LGVN
Jhaveri Nirav S. (Chief Financial Officer) reported special transactions (Non-P/S).
Jhaveri Nirav S. (Chief Financial Officer) reported special transactions (Non-P/S).
SEC Filing: LGVN
Click to view the official SEC document.
www.sec.gov
October 5, 2026 at 11:18 PM
🚨 $LGVN
Jhaveri Nirav S. (Chief Financial Officer) reported special transactions (Non-P/S).
Jhaveri Nirav S. (Chief Financial Officer) reported special transactions (Non-P/S).
🚨 $LGVN
Lehr Paul T (General Counsel, Secretary) reported special transactions (Non-P/S).
Lehr Paul T (General Counsel, Secretary) reported special transactions (Non-P/S).
SEC Filing: LGVN
Click to view the official SEC document.
www.sec.gov
October 5, 2026 at 11:17 PM
🚨 $LGVN
Lehr Paul T (General Counsel, Secretary) reported special transactions (Non-P/S).
Lehr Paul T (General Counsel, Secretary) reported special transactions (Non-P/S).
🚨 $LGVN
Willard Stephen H (Chief Executive Officer) reported special transactions (Non-P/S).
Willard Stephen H (Chief Executive Officer) reported special transactions (Non-P/S).
SEC Filing: LGVN
Click to view the official SEC document.
www.sec.gov
October 5, 2026 at 11:18 PM
🚨 $LGVN
Willard Stephen H (Chief Executive Officer) reported special transactions (Non-P/S).
Willard Stephen H (Chief Executive Officer) reported special transactions (Non-P/S).
After ELPIS II: can frailty and XPRIZE carry laromestrocel? Cash is the clock.
Longeveron (#$LGVN) Stock Hub: Can Frailty and XPRIZE Carry Laromestrocel After ELPIS II?
Catalysts + risks: www.merlintrader.com/longeveron-l...
Longeveron (#$LGVN) Stock Hub: Can Frailty and XPRIZE Carry Laromestrocel After ELPIS II?
Catalysts + risks: www.merlintrader.com/longeveron-l...
October 4, 2026 at 7:34 PM
After ELPIS II: can frailty and XPRIZE carry laromestrocel? Cash is the clock.
Longeveron (#$LGVN) Stock Hub: Can Frailty and XPRIZE Carry Laromestrocel After ELPIS II?
Catalysts + risks: www.merlintrader.com/longeveron-l...
Longeveron (#$LGVN) Stock Hub: Can Frailty and XPRIZE Carry Laromestrocel After ELPIS II?
Catalysts + risks: www.merlintrader.com/longeveron-l...
#LGVN Longeveron to Participate in Three Longevity/Aging Investment Conferences
https://www.stocktitan.net/news/LGVN/longeveron-to-participate-in-three-longevity-aging-investment-lq4zqfsdb7ki.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/LGVN/longeveron-to-participate-in-three-longevity-aging-investment-lq4zqfsdb7ki.html?utm_source=stocktitan-bluesky&utm_medium=social
Longeveron to Participate in Three Longevity/Aging Investment Conferences
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
September 30, 2026 at 8:05 PM
#LGVN Longeveron to Participate in Three Longevity/Aging Investment Conferences
https://www.stocktitan.net/news/LGVN/longeveron-to-participate-in-three-longevity-aging-investment-lq4zqfsdb7ki.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/LGVN/longeveron-to-participate-in-three-longevity-aging-investment-lq4zqfsdb7ki.html?utm_source=stocktitan-bluesky&utm_medium=social
🚨 $LGVN
On September 16, 2026, Longeveron Inc. a clinical-stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, issued a press release announcing topline results from ELPIS II, its Phase 2b clinical trial evaluating th...
On September 16, 2026, Longeveron Inc. a clinical-stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, issued a press release announcing topline results from ELPIS II, its Phase 2b clinical trial evaluating th...
SEC Filing: LGVN
Click to view the official SEC document.
www.sec.gov
September 23, 2026 at 8:04 PM
🚨 $LGVN
On September 16, 2026, Longeveron Inc. a clinical-stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, issued a press release announcing topline results from ELPIS II, its Phase 2b clinical trial evaluating th...
On September 16, 2026, Longeveron Inc. a clinical-stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, issued a press release announcing topline results from ELPIS II, its Phase 2b clinical trial evaluating th...
⚠️ $LGVN Longeveron: ELPIS II Phase 2b trial missed primary endpoint (RVEF improvement, p=0.8336); no deaths in treated arm but MACE reduction not statistically significant; exploring options to maximize shareholder value [HIGH RISK]
September 23, 2026 at 10:00 PM
⚠️ $LGVN Longeveron: ELPIS II Phase 2b trial missed primary endpoint (RVEF improvement, p=0.8336); no deaths in treated arm but MACE reduction not statistically significant; exploring options to maximize shareholder value [HIGH RISK]
Longeveron (#$LGVN) Stock Hub
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/longeveron-l...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/longeveron-l...
September 19, 2026 at 7:57 PM
Longeveron (#$LGVN) Stock Hub
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/longeveron-l...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/longeveron-l...
Small-cap stocks with strong volume declines, Thu Sept 17th - #$RUBI #$TLNC #$RTG #$PNTG #$PAL #$OFS #$MRLN #$LGVN #$JAGX #$IPHA #$FLNC #$DSP #$PAII #$FCRS #$CPAC - More: crystalequityresearch.com/leading-indi... - #smallcap
Leading Indicators, Thursday September 17, 2026 – Crystal Equity Research
crystalequityresearch.com
September 17, 2026 at 9:26 PM
🚀 Zacks Small Cap Research - LGVN Posts Disappointing Trial Results
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-lgvn-posts-disappointing-trial-results/
#LGVN #Lon#LGVNo#Longeveronr#LaromestrocelP#HLHS##ELPISII##Phase2br#AlzheimersDiseasea#AgingRelatedFrailtya href="/hashtag/R" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#R href="/hashtag/MACE" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MACE
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-lgvn-posts-disappointing-trial-results/
#LGVN #Lon#LGVNo#Longeveronr#LaromestrocelP#HLHS##ELPISII##Phase2br#AlzheimersDiseasea#AgingRelatedFrailtya href="/hashtag/R" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#R href="/hashtag/MACE" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MACE
September 17, 2026 at 3:56 PM
🚀 Zacks Small Cap Research - LGVN Posts Disappointing Trial Results
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-lgvn-posts-disappointing-trial-results/
#LGVN #Lon#LGVNo#Longeveronr#LaromestrocelP#HLHS##ELPISII##Phase2br#AlzheimersDiseasea#AgingRelatedFrailtya href="/hashtag/R" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#R href="/hashtag/MACE" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MACE
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-lgvn-posts-disappointing-trial-results/
#LGVN #Lon#LGVNo#Longeveronr#LaromestrocelP#HLHS##ELPISII##Phase2br#AlzheimersDiseasea#AgingRelatedFrailtya href="/hashtag/R" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#R href="/hashtag/MACE" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MACE
#$LGVN Posts Disappointing Trial Results buff.ly/H9Klz9M
September 17, 2026 at 3:16 PM
#$LGVN Posts Disappointing Trial Results buff.ly/H9Klz9M
